Human Monoclonal Antibodies as Candidate Therapeutics Against Emerging Viruses and HIV-1

被引：0

作者：

Zhongyu Zhu ^{[1
]}

Ponraj Prabakaran ^{[1
,2
]}

Weizao Chen ^{[1
]}

Christopher C.Broder ^{[3
]}

Rui Gong ^{[4
]}

Dimiter S.Dimitrov ^{[1
]}

机构：

[1] Protein Interactions Group, National Cancer Institute, National Institutes of Health

[2] Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences

[3] Basic Research Program, Science Applications International Corporation-Frederick, Inc.

[4] Department of Microbiology and Immunology, Uniformed Services University

来源：

Virologica Sinica | 2013年 / 02期

基金：

美国国家卫生研究院;

关键词：

Antibodies; Viruses; SARS-CoV; Hendra virus; Nipah Virus;

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

引用

页码：71 / 80

页数：10

共 25 条

[1] Broadly neutralizing antibodies against HIV-1: Templates for a vaccine[J] . Marit J. van Gils,Rogier W. Sanders.Virology . 2013 (1)
[2] Characterization of human IgG repertoires in an acute HIV-1 infection
Chen, Weizao
Prabakaran, Ponraj
Zhu, Zhongyu
Feng, Yang
Streaker, Emily D.
Dimitrov, Dimiter S.
[J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2012, 93 (03) : 399 - 407
[3] HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design[J] . Mattia Bonsignori,S. Munir Alam,Hua-Xin Liao,Laurent Verkoczy,Georgia D. Tomaras,Barton F. Haynes,M. Anthony Moody.Trends in Microbiology . 2012 (11)
[4] Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies[J] . Peter D. Kwong,John R. Mascola.Immunity . 2012 (3)
[5] Candidate Antibody-Based Therapeutics Against HIV-1
Gong, Rui
Chen, Weizao
Dimitrov, Dimiter S.
[J]. BIODRUGS, 2012, 26 (03) : 143 - 162
[6] A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo
Meuleman, Philip
Catanese, Maria Teresa
Verhoye, Lieven
Desombere, Isabelle
Farhoudi, Ali
Jones, Christopher T.
Sheahan, Timothy
Grzyb, Katarzyna
Cortese, Riccardo
Rice, Charles M.
Leroux-Roels, Geert
Nicosia, Alfredo
[J]. HEPATOLOGY, 2012, 55 (02) : 364 - 372
[7] Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential[J] . Melissa M.Coughlin,Bellur S.Prabhakar.Rev. Med. Virol. . 2012 (1)
[8] Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies
Verkoczy, Laurent
Kelsoe, Garnett
Moody, M. Anthony
Haynes, Barton F.
[J]. CURRENT OPINION IN IMMUNOLOGY, 2011, 23 (03) : 383 - 390
[9] Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms
Shedlock, Devon J.
Bailey, Michael A.
Popernack, Paul M.
Cunningham, James M.
Burton, Dennis R.
Sullivan, Nancy J.
[J]. VIROLOGY, 2010, 401 (02) : 228 - 235
[10] Dissection of the IgNAR V Domain: Molecular Scanning and Orthologue Database Mining Define Novel IgNAR Hallmarks and Affinity Maturation Mechanisms[J] . B.J. Fennell,A. Darmanin-Sheehan,S.E. Hufton,V. Calabro,L. Wu,M.R. Müller,W. Cao,D. Gill,O. Cunningham,W.J.J. Finlay.Journal of Molecular Biology . 2010 (2)

← 1 2 3 →